Abstract
Ischemia-reperfusion injury (IRI) remains a global public health problem, with increasing incidence which is associated with significant morbidity and mortality. The duration of blood flow deprivation is a critical risk factor in conditions such as myocardial infarction (MI), stroke, solid organ transplantation, and hemorrhagic shock. From a pathophysiological perspective, IRI leads to numerous architectural, cellular, and metabolic changes in tissues. Moreover, local and systemic inflammation occurs after reperfusion of ischemic tissue. Clinically, the treatment of cases with IRI is frequently restricted to supportive maneuvers, with no exact target-oriented therapies validated so far. Recent research reveals the efficacy of stem cells as a promising therapeutic approach. Additionally, exosomes have been suggested to exert a significant impact on the stimulation of useful signaling pathways in different cardiovascular diseases. This review provided an overview of the new treatment strategies such as stem cell therapy (SCT) and exosome-based treatments for improving myocardial IRI.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
